Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion

Czyz, Anna; Lewandowski, Krzysztof; Kroll, Renata; Komarnicki, Mieczysław
December 2010
Medical Oncology;Dec2010, Vol. 27 Issue 4, p1123
Academic Journal
Presence of the Philadelphia chromosome in acute lymphoblastic leukemia is the single most adverse prognostic marker associated with high risk of disease relapse and poor prognosis. Allogeneic haematopoietic stem cell transplantation is considered as the only curative option in adults with Philadelphia-positive acute lymphoblastic leukemia, but relapse remains the main cause of treatment failure. Moreover, long-term survival rates are markedly decreased when transplanted patients are not in complete remission. Incorporation of tyrosine kinase inhibitors into transplantation strategy in patients with Philadelphia-positive acute lymphoblastic leukemia may improve prognosis of the disease. Imatinib combined with conventional chemotherapy and used in conjunction with allogeneic hematopoietic stem cell transplantation has improved long-term survival rates. The more potent multikinase inhibitor dasatinib has shown enhanced activity in Philadelphia-positive acute lymphoblastic leukemia and has been approved for the treatment of adults with resistance or intolerance to prior imatinib therapy. Here, we present a case of Philadelphia-positive acute lymphoblastic leukemia primary resistant to imatinib combined with chemotherapy. Subsequently, the patient underwent allogeneic hematopoietic stem cell transplantation as a salvage therapy. Clinical evaluation performed thereafter revealed complete hematologic remission, but with the presence of the minimal residual disease detected at molecular level. Due to imatinib resistance, the therapy with dasatinib was started and complete molecular response was obtained. The consecutive clinical evaluation performed every 3 months during the last 18 months confirmed the absence of molecular minimal residual disease. We believe that inclusion of dasatinib into transplantation strategy allows obtaining sustained molecular remission even in patients resistant to imatinib.


Related Articles

  • Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Fielding, A K; Goldstone, A H // Bone Marrow Transplantation;Mar2008, Vol. 41 Issue 5, p447 

    ALL in which the Philadelphia (Ph) chromosome is detected is one of the few diseases in which there is almost unequivocal agreement that a matched sibling allogeneic haematopoietic stem cell transplant in first CR is the most appropriate therapy for patients within certain age limits. Extension...

  • Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Gruber, F.X.E.; Lamark, T.; Ånonli, A.; Sovershaev, M.A.; Olsen, M.; Gedde-Dahl, T.; Hjort-Hansen, H.; Skogen, B. // Leukemia (08876924);Dec2005, Vol. 19 Issue 12, p2159 

    Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in the ABL gene encoding the ATP binding region likely to cause disease relapse. Early diagnosis and monitoring of these mutations may be important in order to prevent...

  • Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Kikuchi, Hirotoshi; Setoguchi, Tomohiko; Miyazaki, Shinichiro; Yamamoto, Masayoshi; Ohta, Manabu; Kamiya, Kinji; Sakaguchi, Takanori; Konno, Hiroyuki // International Journal of Clinical Oncology;Dec2011, Vol. 16 Issue 6, p741 

    Imatinib mesylate is an effective treatment for recurrent or metastatic gastrointestinal stromal tumors (GISTs), but secondary resistance has been reported. The tyrosine kinase inhibitor sunitinib malate has shown efficacy in imatinib-resistant GISTs, and has been used as second-line therapy for...

  • Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Harnicar, Stephen; Mathew, Sherry // Blood & Lymphatic Cancer: Targets & Therapy;Aug2014, Vol. 4, p61 

    Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR-ABL fusion oncogene, the introduction of tyrosine-kinase inhibitors (TKIs) has dramatically improved the outcomes of this disease. Nilotinib is a...

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Duy, Cihangir; Hurtz, Christian; Shojaee, Seyedmehdi; Cerchietti, Leandro; Huimin Geng; Swaminathan, Srividya; Klemm, Lars; Soo-mi Kweon; Rahul Nahar; Braig, Melanie; Park, Eugene; Yong-mi Kim; Hofmann, Wolf-Karsten; Herzog, Sebastian; Jumaa, Hassan; Koeffler, H. Phillip; Yu, J. Jessica; Heisterkamp, Nora; Graeber, Thomas G.; Hong Wu // Nature;5/19/2011, Vol. 473 Issue 7347, p384 

    Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases. However, even effective TKIs typically fail...

  • Gene expression signatures associated with the resistance to imatinib. Chung, Y.-J.; Kim, T.-M.; Kim, D.-W.; Namkoong, H.; Kim, H. K.; Ha, S.-A.; Kim, S.; Shin, S. M.; Kim, J.-H.; Lee, Y.-J.; Kang, H.-M.; Kim, J. W. // Leukemia (08876924);Sep2006, Vol. 20 Issue 9, p1542 

    Imatinib (imatinib mesylate, STI-571, Gleevec) is a selective BCR-ABL tyrosine kinase inhibitor that has been used as a highly effective chemoagent for treating chronic myelogenous leukemia. However, the initial response to imatinib is often followed by the recurrence of a resistant form of the...

  • Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment. Sleijfer, Stefan; Wiemer, Erik; Seynaeve, Caroline; Verweij, Jaap // Oncologist;Jun2007, Vol. 12 Issue 6, p719 

    Gastrointestinal stromal tumor (GIST) is one of the first solid tumor types in which a tyrosine kinase inhibitor, imatinib, has become standard of care for patients with advanced disease. Although imatinib yields antitumor activity in the vast majority of patients, it is likely that all patients...

  • Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia. Soh, Sheila Xinxuan; Lim, Joshua Yew Suang; Huang, John W. J.; Jiang, Nan; Yeoh, Allen Eng Juh; Ong, S. Tiong // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    A broad range of anti-cancer agents, including glucocorticoids (GCs) and tyrosine kinase inhibitors (TKIs), kill cells by upregulating the pro-apoptotic BCL2 family member, BIM. A common germline deletion in the BIM gene was recently shown to favor the production of non-apoptotic BIM isoforms,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics